Results 31 to 40 of about 14,499 (181)

Efficacy and Safety of Adjunctive Cilostazol to Clopidogrel‐Treated Diabetic Patients With Symptomatic Lower Extremity Artery Disease in the Prevention of Ischemic Vascular Events

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Type 2 diabetes mellitus is a risk factor for lower extremity arterial disease. Cilostazol expresses antiplatelet, anti‐inflammatory, and vasodilator actions and improves the claudication intermittent symptoms. We investigated the efficacy and
Kallirroi Kalantzi, Nikolaos Tentolouris, Andreas J. Melidonis, Styliani Papadaki, Michail Peroulis, Konstantinos A. Amantos, George Andreopoulos, George I. Bellos, Dimitrios Boutel, Magdalini Bristianou, Dimitrios Chrisis, Nikolaos A. Dimitsikoglou, John Doupis, Chrysoula Georgopoulou, Stergios A. Gkintikas, Styliani Iraklianou, Κonstantinos Kanellas, Kalliopi Kotsa, Theocharis Koufakis, Maria Kouroglou, Anastasios G. Koutsovasilis, Leonidas Lanaras, Eirini Liouri, Charalampos Lixouriotis, Akrivi Lykoudi, Efthymia Mandalaki, Evanthia Papageorgiou, Nikolaos Papanas, Spyridon Rigas, Maria I. Stamatelatou, Ioannis Triantafyllidis, Aikaterini Trikkalinou, Aikaterini N. Tsouka, Ourania Zacharopoulou, Christos Zoupas, Ioannis Tsolakis, Alexandros D. Tselepis   +36 more
doaj   +1 more source

A systematic review of exercise testing in patients with intermittent claudication: A focus on test standardisation and reporting quality in randomised controlled trials of exercise interventions.

PLoS ONE, 2021
A systematic review was conducted to identify the range of terminology used in studies to describe maximum walking distance and the exercise testing protocols, and testing modalities used to measure it in patients with intermittent claudication.
Stefan T Birkett, Amy E Harwood, Edward Caldow, Saïd Ibeggazene, Lee Ingle, Sean Pymer   +5 more
doaj   +1 more source

A Modified Technique for Converting Retrograde Femoral Artery Access to Antegrade Access With the Assistance of a Long Sheath

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Percutaneous femoral access serves as the cornerstone of endovascular therapy of lower extremity arterial disease. In complex cases, the arterial disease of lower extremity are involve in ipsilateral iliac artery pathology, which conventional treatment strategies typically require multiple punctures or staged procedures.
Guangfeng Zheng, Ze Wang, Chuanyong Li, Qiang Zhang, Zhichang Pan, Shuming Shi, Jianjie Rong   +6 more
wiley   +1 more source

Validation of the European Society of Cardiology Ischemic and Bleeding Risk Criteria for Risk Stratification After Endovascular Therapy in Japanese Patients With Lower Extremity Artery Disease

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background The European Society of Cardiology (ESC) guidelines for peripheral artery disease recommend antithrombotic strategies based on high ischemic risk (HIR) and high bleeding risk (HBR) criteria. However, their prognostic value in patients with lower extremity artery disease (LEAD) undergoing endovascular therapy (EVT) remains unclear ...
Hirokazu Shimono, Daisuke Kanda, Akihiro Tokushige, Nobuhiro Ito, Yutaro Nomoto, Hiroyuki Tabata, Kenta Ohmure, Takuro Kubozono, Mitsuru Ohishi   +8 more
wiley   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Pelvic venous disorders in women: Diagnosis and management for gynecologists

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Pelvic venous disorders (PeVD) are an underrecognized yet significant cause of chronic pelvic pain (CPP) in reproductive‐aged women, characterized by venous reflux, obstruction, or both. This clinical opinion provides a practical overview of PeVD for gynecologists, outlining its pathophysiology, common presentations, diagnostic approach, and ...
Tiffany Ni, Inbar Friedman, Jessica Smith, Brian Liu, Mary Melchior, Andrew D. Brown   +5 more
wiley   +1 more source

Pentoxifylline for intermittent claudication

Cochrane Database of Systematic Reviews, 2020
Intermittent claudication (IC) is a symptom of peripheral arterial disease (PAD) and is associated with high morbidity and mortality. Pentoxifylline, one of many drugs used to treat IC, acts by decreasing blood viscosity, improving erythrocyte flexibility, and promoting microcirculatory flow and tissue oxygen concentration.
Cathryn, Broderick, Rachel, Forster, Mohammed, Abdel-Hadi, Kareem, Salhiyyah   +3 more
openaire   +3 more sources

Buflomedil for intermittent claudication [PDF]

Cochrane Database of Systematic Reviews, 2013
Intermittent claudication (IC) is pain caused by chronic occlusive arterial disease, that develops in a limb during exercise and is relieved with rest. Buflomedil is a vasoactive agent used to treat peripheral vascular disease. However, its clinical efficacy for IC has not yet been critically examined.
De Backer, Tine, Vander Stichele, Robert
openaire   +2 more sources

Arterial claudication

Vascular Investigation and Therapy, 2022
Arterial claudication is generally the revealing form of clinically symptomatic lower extremity artery disease. It is defined as a pain of limb muscles that occurs during exercise and is relieved within 10 min when exercise is lowered or stopped ...
Pierre Abraham, Simon Lecoq, Jeanne Hersant, Samir Henni   +3 more
doaj   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source